Peptide hormones: Review of current and emerging uses by nasal delivery (Q33933164)

30 July 2017

title

Peptide hormones: Review of current and emerging uses by nasal delivery (English)

1 reference

30 July 2017

Pontiroli AE

1

1 reference

30 July 2017

language of work or name

English

0 references

publication date

1 January 1998

1 reference

Advanced Drug Delivery Reviews

30 July 2017

published in

1 reference

30 July 2017

volume

29

1 reference

30 July 2017

issue

1-2

1 reference

30 July 2017

page(s)

81-87

1 reference

Nasal administration of an ACTH(4-9) peptide analogue with dimethyl-beta-cyclodextrin as an absorption enhancer: pharmacokinetics and dynamics

30 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900062-8

7 January 2021

Protection of nonobese diabetic mice from diabetes by intranasal or subcutaneous administration of insulin peptide B-(9-23)

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900062-8

7 January 2021

Effect of 14 days' subcutaneous administration of the human amylin analogue, pramlintide (AC137), on an intravenous insulin challenge and response to a standard liquid meal in patients with IDDM.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900062-8

7 January 2021

A 35 amino acid fragment of leptin inhibits feeding in the rat.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900062-8

7 January 2021

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900062-8

7 January 2021

Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900062-8

7 January 2021

Intranasal drug delivery. Potential advantages and limitations from a clinical pharmacokinetic perspective

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900062-8

7 January 2021

Intranasal administration of peptide hormones: factors affecting transmucosal absorption

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900062-8

7 January 2021

Bioavailability of leuprolide acetate following nasal and inhalation delivery to rats and healthy humans

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900062-8

7 January 2021

The bioavailability of intranasal salmon calcitonin in healthy volunteers with and without a permeation enhancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900062-8

7 January 2021

Effects of oral alendronate and intranasal salmon calcitonin on bone mass and biochemical markers of bone turnover in postmenopausal women with osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900062-8

7 January 2021

Intranasal and intramuscular human calcitonin in female osteoporosis and in Paget's disease of bones: a pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900062-8

7 January 2021

Nasal absorption in the rat. III. Effect of lysophospholipids on insulin absorption and nasal histology

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900062-8

7 January 2021

Intranasal Administration of Insulin With Phospholipid as Absorption Enhancer: Pharmacokinetics in Normal Subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900062-8

7 January 2021

Intranasal insulin: the effects of three dose regimens on postprandial glycaemic profiles in type II diabetic subjects.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900062-8

7 January 2021

Intranasal insulin therapy: the clinical realities

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900062-8

7 January 2021

Intranasal glucagon as remedy for hypoglycemia. Studies in healthy subjects and type I diabetic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900062-8

7 January 2021

Glucose recovery after intranasal glucagon during hypoglycaemia in man

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900062-8

7 January 2021

Intranasal glucagon treatment relieves hypoglycaemia in children with type 1 (insulin-dependent) diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900062-8

7 January 2021

Pharmacokinetics of intranasal, intramuscular and intravenous glucagon in healthy subjects and diabetic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900062-8

7 January 2021

The hypotonic effect of intranasal and intravenous glucagon in gastrointestinal radiology

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900062-8

7 January 2021

Growth hormone-releasing activity of hexarelin, a new synthetic hexapeptide, after intravenous, subcutaneous, intranasal, and oral administration in man.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900062-8

7 January 2021

Growth hormone releasing activity by intranasal administration of a synthetic hexapeptide (hexarelin)

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900062-8

7 January 2021

Intranasal administration of the GHRP hexarelin accelerates growth in short children

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900062-8

7 January 2021

Short-term administration of intranasal or oral Hexarelin, a synthetic hexapeptide, does not desensitize the growth hormone responsiveness in human aging

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900062-8

7 January 2021

Bioavailability and bioactivity of three different doses of nasal growth hormone (GH) administered to GH-deficient patients: comparison with intravenous and subcutaneous administration

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900062-8

7 January 2021

Epithelial transport and bioavailability of intranasally administered human growth hormone formulated with the absorption enhancers didecanoyl-L-alpha-phosphatidylcholine and alpha-cyclodextrin in rabbits

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900062-8

7 January 2021

Prevention of the Dawn phenomenon (early morning hyperglycemia) in insulin-dependent diabetes mellitus by bedtime intranasal administration of a long-acting somatostatin analog.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900062-8

7 January 2021

Nasal absorption of propranolol in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900062-8

7 January 2021

Nasal Absorption of Natural Contraceptive Steroids in Rats—Progesterone Absorption

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900062-8

7 January 2021

Intranasal apomorphine in parkinsonian on-off fluctuations

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900062-8

7 January 2021

10.1016/S0169-409X(97)00062-8

Identifiers

DOI

1 reference

30 July 2017

1 reference